Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab

Blinatumomab has demonstrated significant efficacy in adult and pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-cell ALL) and patients with measurable residual disease (MRD). This review aimed to compare median relapse-free survival (RFS) and median overall sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantarjian, Hagop M., Logan, Aaron C., Zaman, Faraz, Gökbuget, Nicola, Bargou, Ralf C., Zeng, Yi, Zugmaier, Gerhard, Locatelli, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563488/
https://www.ncbi.nlm.nih.gov/pubmed/37822571
http://dx.doi.org/10.1177/20406207231201454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563488/
https://www.ncbi.nlm.nih.gov/pubmed/37822571
http://dx.doi.org/10.1177/20406207231201454

Ejemplares similares